000 01250 a2200313 4500
005 20250516113524.0
264 0 _c20130306
008 201303s 0 0 eng d
022 _a1538-067X
024 7 _a10.1188/12.CJON.E164-E172
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMcCann, Sue
245 0 0 _aAdverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
_h[electronic resource]
260 _bClinical journal of oncology nursing
_cOct 2012
300 _aE164-72 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAntineoplastic Agents
_xadverse effects
650 0 4 _aClinical Trials, Phase III as Topic
650 0 4 _aDiphtheria Toxin
_xadverse effects
650 0 4 _aHumans
650 0 4 _aInterleukin-2
_xadverse effects
650 0 4 _aLymphoma, T-Cell
_xdrug therapy
650 0 4 _aRecombinant Fusion Proteins
_xadverse effects
650 0 4 _aSkin Neoplasms
_xdrug therapy
700 1 _aAkilov, Oleg E
700 1 _aGeskin, Larisa
773 0 _tClinical journal of oncology nursing
_gvol. 16
_gno. 5
_gp. E164-72
856 4 0 _uhttps://doi.org/10.1188/12.CJON.E164-E172
_zAvailable from publisher's website
999 _c22145689
_d22145689